Wockhardt Ltd
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
- Market Cap ₹ 20,039 Cr.
- Current Price ₹ 1,233
- High / Low ₹ 1,335 / 323
- Stock P/E
- Book Value ₹ 221
- Dividend Yield 0.00 %
- ROCE -0.83 %
- ROE -12.1 %
- Face Value ₹ 5.00
Pros
- Company's working capital requirements have reduced from 45.3 days to 20.7 days
Cons
- Stock is trading at 5.57 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -2.90%
- The company has delivered a poor sales growth of -4.73% over past five years.
- Company has a low return on equity of -7.58% over last 3 years.
- Promoters have pledged 36.1% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Allcap BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE SmallCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5,609 | 4,830 | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 2,949 | |
3,606 | 3,805 | 3,772 | 3,959 | 4,002 | 3,935 | 3,604 | 2,725 | 2,771 | 2,932 | 2,549 | 2,707 | 2,770 | |
Operating Profit | 2,004 | 1,026 | 709 | 494 | 13 | 2 | -38 | 119 | -63 | 298 | 102 | 91 | 179 |
OPM % | 36% | 21% | 16% | 11% | 0% | 0% | -1% | 4% | -2% | 9% | 4% | 3% | 6% |
187 | 88 | 67 | 66 | 114 | -238 | 116 | 133 | 975 | -163 | -173 | 17 | 57 | |
Interest | 215 | 83 | 55 | 129 | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 296 |
Depreciation | 122 | 140 | 145 | 142 | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 223 | 222 |
Profit before tax | 1,853 | 891 | 575 | 289 | -247 | -641 | -351 | -247 | 417 | -411 | -624 | -420 | -282 |
Tax % | 14% | 5% | 28% | 13% | -9% | 4% | -38% | -82% | -65% | -32% | -0% | 12% | |
1,594 | 843 | 413 | 252 | -226 | -667 | -217 | -43 | 688 | -279 | -621 | -472 | -295 | |
EPS in Rs | 111.87 | 58.91 | 28.30 | 17.45 | -13.62 | -42.30 | -13.52 | -4.81 | 47.64 | -16.94 | -38.80 | -30.18 | -19.12 |
Dividend Payout % | 3% | 13% | 54% | 0% | -56% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -5% |
5 Years: | -5% |
3 Years: | 1% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 44% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | 39% |
3 Years: | 45% |
1 Year: | 265% |
Return on Equity | |
---|---|
10 Years: | -1% |
5 Years: | 0% |
3 Years: | -8% |
Last Year: | -12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 77 | 77 |
Reserves | 2,351 | 3,228 | 3,362 | 3,720 | 3,281 | 2,797 | 2,619 | 2,616 | 3,321 | 3,777 | 3,282 | 3,282 | 3,318 |
2,369 | 2,205 | 2,309 | 2,677 | 4,160 | 3,748 | 3,375 | 3,582 | 2,674 | 2,198 | 2,184 | 2,356 | 2,343 | |
1,248 | 1,134 | 1,213 | 1,622 | 1,486 | 1,528 | 1,764 | 1,894 | 1,696 | 2,168 | 2,113 | 1,899 | 1,850 | |
Total Liabilities | 6,023 | 6,622 | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,746 | 8,215 | 7,651 | 7,614 | 7,588 |
1,990 | 2,295 | 2,123 | 2,809 | 2,773 | 2,888 | 3,058 | 3,502 | 3,343 | 3,462 | 3,042 | 2,881 | 4,254 | |
CWIP | 491 | 708 | 1,007 | 1,036 | 1,244 | 1,433 | 1,445 | 1,585 | 1,379 | 1,342 | 1,539 | 1,722 | 481 |
Investments | 3 | 577 | 341 | 0 | 563 | 214 | 0 | 0 | 0 | 0 | 0 | 0 | 48 |
3,539 | 3,043 | 3,468 | 4,228 | 4,403 | 3,593 | 3,309 | 3,060 | 3,024 | 3,411 | 3,070 | 3,011 | 2,805 | |
Total Assets | 6,023 | 6,622 | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,746 | 8,215 | 7,651 | 7,614 | 7,588 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,532 | 1,476 | 355 | -42 | -269 | 68 | 183 | 649 | -287 | 413 | 153 | 219 | |
1,074 | -823 | -222 | -105 | -684 | 635 | 93 | -147 | 1,471 | -204 | -118 | -138 | |
-2,246 | -601 | -76 | 193 | 1,254 | -769 | -776 | -680 | -1,171 | -71 | -315 | 334 | |
Net Cash Flow | 360 | 52 | 57 | 46 | 301 | -66 | -500 | -178 | 13 | 138 | -280 | 415 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 62 | 36 | 60 | 91 | 94 | 89 | 130 | 159 | 124 | 104 | 110 | 81 |
Inventory Days | 221 | 201 | 250 | 249 | 243 | 174 | 183 | 209 | 256 | 222 | 216 | 201 |
Days Payable | 132 | 113 | 136 | 144 | 117 | 122 | 187 | 272 | 223 | 265 | 285 | 240 |
Cash Conversion Cycle | 151 | 124 | 175 | 196 | 220 | 141 | 126 | 97 | 157 | 60 | 41 | 41 |
Working Capital Days | 42 | 9 | 43 | 97 | 96 | -16 | 7 | -47 | 122 | 62 | 53 | 21 |
ROCE % | 42% | 18% | 10% | 7% | -1% | -1% | -1% | 0% | 12% | 1% | -0% | -1% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
18 Nov - Intimation of lost share certificate by shareholder.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
14 Nov - Intimation of lost share certificate by shareholder.
-
Statement On Deviation Or Variation Of Funds Raised Through Qualified Institutions Placement For The Quarter Ended 30Th June, 2024 Confirming That There Has Been No Deviation In The Utilization Of Issue Proceeds.
13 Nov - No deviation in fund utilization from QIP proceeds.
-
Please Find Enclosed Herewith The Monitoring Agency Report Towards Utilization Of Proceeds Of Qualified Institutions Placement ('QIP') For The Quarter Ended September 30, 2024, Issued By CRISIL Ratings Limited.
13 Nov - Monitoring Agency Report for QIP proceeds utilization.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Oct 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Mar 2022TranscriptNotesPPT
Market Position
The Co. is amongst top 3 Indian generic companies in the UK and 6th Largest generic supplier in Ireland in Retail and Hospital channels.
Its Wepox is the leader in Erythropoetin market (market share =21%)and Methylcobalamin Brand is no. 1 with (Methycobal= 26.7% market share) {#https://www.bseindia.com/bseplus/AnnualReport/532300/73832532300.pdf#page=34 #}